Ibogaine vs Ketamine

These two get mentioned in the same breath because both are dissociative, both are sold by clinics for addiction, and neither is approved for it. Almost everything else about them differs.

Side by side

The legal difference is not cosmetic

Ketamine is Schedule III in the United States. A physician can prescribe it, and the clinics that give it for depression or addiction are practising off-label medicine, which is ordinary and lawful.

Ibogaine is Schedule I. There is no lawful prescription, and the treatment happens in other jurisdictions or outside the law.

That difference shapes everything downstream: who is in the room, whether there is a licence to lose, whether an adverse event gets reported anywhere.

What ketamine has actually shown for addiction

More than ibogaine, and less than its reputation.

The only meta-analysis of ketamine in substance use disorder pooled 15 randomised trials and 798 participants, of which seven contributed abstinence data. It declares no conflicts of interest. Its two headline results are worth reading together.

The authors’ own conclusion is that the evidence suggests a short-term signal and remains insufficient to establish efficacy or safety.

The best single trial is an alcohol study of 96 people run at a UK university with public funding. Ketamine plus therapy increased days abstinent by about ten percentage points over placebo, with a confidence interval reaching down to 1.1 per cent. It also found no significant difference in relapse rate, which was one of its two co-primary outcomes. The authors call it a proof-of-concept study and note the wide intervals. Anyone citing it as evidence that ketamine treats alcoholism has read the abstract and not the results.

What ibogaine has shown

Set out fully on what the trials found, and briefly: no randomised controlled trial has published drug-use outcomes. Two randomised blinded trials completed in 2024 and neither has reported. The published evidence is case series and surveys, the largest prospective one covering thirty people.

On the question this page asks, ketamine has more evidence. Both have less than the marketing implies.

The harms are not comparable in kind

This is where the comparison becomes practical.

Ibogaine fails acutely. The danger is concentrated in a single session and it is cardiac. In a hospital study of fourteen patients, half exceeded a corrected QT interval of 500 milliseconds and mean maximum prolongation was 95 milliseconds. Ibogaine and the heart covers the screening and monitoring that follow from it. A person either gets through the session or they do not.

Ketamine fails cumulatively. Its serious harms build with repeated exposure, which matters because the treatment model is repeated by design.

• Bladder damage. Among heavy recreational users the reported prevalence of urinary symptoms is high, though the figures are inflated by how those samples are gathered. A careful 2025 review reports 44 to 77 per cent for lower urinary tract symptoms in recreational users, falling to 2 to 27 per cent in studies using better case ascertainment, and finds that across 14 randomised trials in psychiatric treatment urological symptoms differed little between ketamine and comparison arms. Its own conclusion is that there is no convincing evidence of ketamine-associated uropathy arising in therapeutic contexts. That is worth quoting, because the recreational figures are usually the ones repeated.
• Dependence. The label describes physical dependence with prolonged use, including craving and withdrawal. In a survey of recreational users, 17 per cent met dependence criteria. Rates reported in supervised psychiatric treatment are far lower.
• Cognition. Deficits are documented in frequent heavy users, with increasing use over a year tracking declining working memory.

The published caution from a 2025 review is precise: clinicians are advised to exercise care when prescribing off-label, with attention to dose, frequency, duration and route.

What nobody has done

No study has compared these two drugs in humans. No trial, no cohort, and no registered study sets one against the other. There is no evidence that one works better than the other, because the experiment has never been run.

If someone tells you ibogaine outperforms ketamine, or the reverse, ask where that comes from. It is not from a comparison.

One thing they share

Neither addresses what the follow-up literature says is the hard part.

Across both fields the same pattern shows: an effect that is largest early and smaller later, in populations selected for being well enough to be treated. In the ibogaine follow-up studies, most of the difficulty people described came after treatment, not during it. In the ketamine meta-analysis, the benefit vanished into non-significance somewhere between one and six months.

Both are single interventions being asked to solve something that behaves chronically.